Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 18 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaRecruitingNCT06151236Phase 2
• A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesRecruitingNCT06150664Phase 1
• Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical CancerNot yet recruitingNCT06149767Phase 2
• Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)RecruitingNCT06149481Phase 1/2
• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast CancerRecruitingNCT06149130Phase 2
• Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal CancerRecruitingNCT06148402Phase 2
• Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid CancerNot yet recruitingNCT06146985Phase 2
• Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant TherapyNot yet recruitingNCT06146777Phase 3
• Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
• A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular CarcinomaNot yet recruitingNCT06143579Phase 2
• A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Not yet recruitingNCT06142617Phase 2
• Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerRecruitingNCT06141226Phase 2
• Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular CarcinomaRecruitingNCT06141109Phase 1/2
• Apatinib Combined With Camrelizumab in Treating Participants With Advanced ChordomaRecruitingNCT06140732Phase 2
• European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]RecruitingNCT06137378Phase 2
• A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Not yet recruitingNCT06136988Phase 1/2
• Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerNot yet recruitingNCT06134193Phase 2
• Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular CarcinomaRecruitingNCT06133062Phase 2
• Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06132828Phase 1
• A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruitingNCT06132217Phase 1/2
• A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyRecruitingNCT06129864Phase 3
• Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.Not yet recruitingNCT06128460Phase 2
• Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLCRecruitingNCT06127303Phase 2
• The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical StudyRecruitingNCT06125080Phase 2
• Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular CarcinomaNot yet recruitingNCT06124001Phase 1/2
• BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerRecruitingNCT06123884Phase 2/3
• A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2
• Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell CarcinomaRecruitingNCT06122493Phase 2
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingNCT06121180Phase 2
• Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 MutationsNot yet recruitingNCT06118658Phase 2
• Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable ResponseRecruitingNCT06116461Phase 4
• Palbociclib and Pembrolizumab in SarcomaRecruitingNCT06113809Phase 1
• BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06111326Phase 1/2
• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationRecruitingNCT06110572Phase 1/2
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2
• A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung CancerRecruitingNCT06108726Phase 2
• Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06107114Phase 2
• A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)RecruitingNCT06103864Phase 3
• Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCCRecruitingNCT06102395Phase 3
• Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCCRecruitingNCT06100497Phase 2
• Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation TherapyNot yet recruitingNCT06099951Phase 2
• Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Phase 3
• Induction Toripalimab and Chemotherapy in Locally Advanced Cervical CancerRecruitingNCT06093438Phase 1/2
• Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
• Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder CarcinomaRecruitingNCT06091124Phase 2
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsRecruitingNCT06090266Phase 1/2
• A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical ResectionNot yet recruitingNCT06089382Phase 3
• Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular InvasionNot yet recruitingNCT06089369Phase 3
• A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingNCT06089330Phase 2
• Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCRecruitingNCT06088771Phase 1/2
• Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline TherapyRecruitingNCT06083844Phase 2
• Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCCRecruitingNCT06081582Phase 2
• AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic CancerNot yet recruitingNCT06080854Phase 2
• Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)RecruitingNCT06079671Phase 3
• 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerRecruitingNCT06079112Phase 1/2
• Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction AdenocarcinomaRecruitingNCT06078709Phase 2
• IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)Not yet recruitingNCT06078657Phase 2
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCRecruitingNCT06078384Phase 2
• A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT06074484Phase 2
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.RecruitingNCT06072612Phase 3
• First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine CarcinomaRecruitingNCT06070740Phase 2
• bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular CarcinomaRecruitingNCT06070636Not applicable
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialRecruitingNCT06069726Phase 2
• Study of Radiotherapy and Pembrolizumab in People With Adrenocortical CarcinomaRecruitingNCT06066333Phase 2
• Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial CancerNot yet recruitingNCT06066216Phase 2
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung CancerRecruitingNCT06065813Phase 2
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingNCT06064097Phase 2
• Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNCT06062563Not applicable
• bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCCRecruitingNCT06061276Not applicable
• Tislelizumab Plus Concurrent Chemoradiation in Older With ESCCRecruitingNCT06061146Phase 2
• Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.RecruitingNCT06060704Phase 2
• Durvalumab and Oleclumab in Resectable PDACRecruitingNCT06060405Phase 2
• DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II StudyRecruitingNCT06059495Phase 2
• Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT06058663Phase 1
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingNCT06058377Phase 3
• Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell CarcinomaRecruitingNCT06056336Phase 2
• Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticRecruitingNCT06056115Not applicable
• Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACCRecruitingNCT06055738Phase 2
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingNCT06053658Phase 2
• Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCCRecruitingNCT06052839Phase 2
• Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingNCT06051851Phase 2
• Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06048926Not applicable
• Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaRecruitingNCT06048484Phase 2
• T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung CancerNot yet recruitingNCT06045767Phase 2
• High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLMRecruitingNCT06045286Phase 1
• Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
• A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast CancerRecruitingNCT06042894Phase 2
• Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT06040177Phase 1/2
• A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT06038396Phase 1/2
• Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
• Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)RecruitingNCT06032845Phase 2
• Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint InhibitorsNot yet recruitingNCT06031480Phase 2
• Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical TrialRecruitingNCT06031285Phase 2
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4
• The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.RecruitingNCT06029829Phase 2
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingNCT06029270Phase 2

← Immune Checkpoint Inhibitors overview